Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 1;41(9):e56-e58.
doi: 10.1097/IAE.0000000000003183.

Reply

Jeffrey S Heier  1 , Rishi P Singh  2 , Charles C Wykoff  3 , Karl G Csaky  4 , Timothy Y Y Lai  5 , Anat Loewenstein  1 , Patricio G Schlottmann  6 , Liliana P Paris  7 , Peter D Westenskow  7 , Carlos Quezada-Ruiz  8   9
Affiliations
Comment

Reply

Jeffrey S Heier et al. Retina. .
No abstract available

PubMed Disclaimer

Comment on

  • THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A Review.
    Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, Schlottmann PG, Paris LP, Westenskow PD, Quezada-Ruiz C. Heier JS, et al. Retina. 2021 Jan 1;41(1):1-19. doi: 10.1097/IAE.0000000000003003. Retina. 2021. PMID: 33136975 Review.
  • Correspondence.
    Achiron RN, Achiron A, Tuuminen R. Achiron RN, et al. Retina. 2021 Sep 1;41(9):e55-e56. doi: 10.1097/IAE.0000000000003184. Retina. 2021. PMID: 33840787 No abstract available.

References

    1. Achiron RN, Achiron A, Tuuminen R. Correlation between systemic and intravitreal angiopoietin-2 protein levels in vitrectomized diabetic patients. Retina. doi: 10.1097/IAE.0000000000003184.
    1. Heier JS, Singh RP, Wykoff CC, et al. The angiopoietin/Tie pathway in retinal vascular diseases: a review. Retina 2021;41:1–19.
    1. Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 2016;8:1265–1288.
    1. Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 2019;11:e10666.
    1. Roche's Faricimab Meets Primary Endpoint and Shows Strong Durability across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of Blindness [Press Release]. Basel, Switzerland: F. Hoffmann-La Roche Ltd.; 2020. Available at: https://www.roche.com/media/releases/med-cor-2020-12-21.htm . Accessed February 23, 2021.

LinkOut - more resources